According to Zacks, “Kezar Life Sciences, Inc. is a bio-technology company. It discovers and develops molecule therapeutics and medicines such as protein homeostasis for autoimmune disorders. The company’s product pipeline consists of KZR-616 which is in clinical stage. Kezar Life Sciences, Inc. is headquartered in South San Francisco, California. “
Separately, William Blair reiterated an outperform rating on shares of Kezar Life Sciences in a research note on Tuesday, March 12th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $24.33.
Kezar Life Sciences (NASDAQ:KZR) last released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.40). On average, research analysts expect that Kezar Life Sciences will post -2.04 EPS for the current fiscal year.
Hedge funds have recently made changes to their positions in the business. BNP Paribas Arbitrage SA grew its stake in shares of Kezar Life Sciences by 131,900.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 2,640 shares of the company’s stock valued at $47,000 after purchasing an additional 2,638 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Kezar Life Sciences by 1.9% in the 4th quarter. BlackRock Inc. now owns 245,932 shares of the company’s stock valued at $5,804,000 after buying an additional 4,486 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Kezar Life Sciences by 126.7% in the 4th quarter. Geode Capital Management LLC now owns 58,046 shares of the company’s stock valued at $1,369,000 after buying an additional 32,441 shares during the period. Spark Investment Management LLC lifted its holdings in shares of Kezar Life Sciences by 125.3% in the 1st quarter. Spark Investment Management LLC now owns 21,200 shares of the company’s stock valued at $376,000 after buying an additional 11,790 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Kezar Life Sciences in the 4th quarter valued at approximately $411,000. Institutional investors own 51.88% of the company’s stock.
Kezar Life Sciences Company Profile
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis.
Featured Article: Risk Tolerance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.